New drug combo aims to wipe out hidden leukemia cells
NCT ID NCT04216563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested adding asciminib (ABL001) to standard tyrosine kinase inhibitor therapy in 7 people with chronic myeloid leukemia who still had traces of cancer. The goal was to see if the combination could eliminate remaining cancer cells. The study was terminated early, so we have limited data on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- asciminib (ABL001)
- What this could lead to
- If successful, this combination could help more CML patients achieve deep remission and possibly stop treatment temporarily.
- What could go wrong
- This was a very small, early-phase trial that was terminated early, so results are limited. The approach may not work for everyone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME NEGATIVE, BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States